Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Carcinoma, Neuroendocrine*/drug therapy ; Carcinoma, Neuroendocrine*/pathology ; Thyroid Neoplasms*/drug therapy ; Thyroid Neoplasms*/pathology ; Hypertension*/drug therapy ; Hypertension*/chemically induced; Humans ; Protein Kinase Inhibitors/adverse effects ; Piperidines/adverse effects
    • Abstract:
      This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hypertension, a well-known adverse effect (AE) of these TKIs. Taken together, TKI-induced hypertension is rarely a dose-limiting side effect. However, with increasing survival times of patients under treatment, hypertension-associated complications can be expected to be on the rise without proper medication.
    • References:
      Thyroid. 2021 Mar;31(3):459-469. (PMID: 32781914)
      Pharmacol Ther. 2018 Dec;192:65-73. (PMID: 29964124)
      Eur Heart J. 2016 Sep 21;37(36):2768-2801. (PMID: 27567406)
      Front Endocrinol (Lausanne). 2018 May 03;9:224. (PMID: 29774010)
      Clin Cancer Res. 2012 Jul 15;18(14):3722-30. (PMID: 22665903)
      Circulation. 2003 Jun 10;107(22):2864-9. (PMID: 12796414)
      Horm Metab Res. 2020 Aug;52(8):562-577. (PMID: 32040962)
      Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Jun 7;54(6):439-444. (PMID: 31262109)
      Thyroid. 2022 May;32(5):515-524. (PMID: 35403447)
      Clin Cancer Res. 2021 Apr 15;27(8):2130-2135. (PMID: 33239432)
      Angiogenesis. 2013 Apr;16(2):289-95. (PMID: 23203441)
      Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2793-800. (PMID: 9409257)
      EXCLI J. 2021 Mar 01;20:506-521. (PMID: 33883980)
      Medicine (Baltimore). 2015 Nov;94(47):e2160. (PMID: 26632749)
      Endocrinol Metab (Seoul). 2021 Jun;36(3):514-524. (PMID: 34154310)
      Endocr Relat Cancer. 2019 Dec 1;27(2):97-110. (PMID: 31804969)
      Oncologist. 2011;16(12):1729-40. (PMID: 22135123)
      Front Endocrinol (Lausanne). 2020 Mar 13;11:102. (PMID: 32231639)
      J Biol Chem. 2006 Sep 8;281(36):26069-80. (PMID: 16835222)
      Ther Adv Med Oncol. 2022 Aug 29;14:17588359221119318. (PMID: 36062046)
      J Hum Hypertens. 2018 Feb;32(2):94-104. (PMID: 29317741)
      Cancer. 2006 Nov 1;107(9):2134-42. (PMID: 17019736)
      Am J Hypertens. 2014 Jan;27(1):3-13. (PMID: 24168915)
      J Clin Oncol. 2012 Jan 10;30(2):134-41. (PMID: 22025146)
      Eur J Endocrinol. 2013 Apr 15;168(5):779-86. (PMID: 23462866)
      J Clin Oncol. 2020 Aug 20;38(24):2773-2781. (PMID: 32584630)
      Clin Cancer Res. 2009 Apr 1;15(7):2207-14. (PMID: 19318488)
      Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. (PMID: 17253471)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      J Clin Oncol. 2011 Jul 1;29(19):2660-6. (PMID: 21606412)
      Health Technol Assess. 2019 Feb;23(8):1-144. (PMID: 30821231)
      Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. (PMID: 34118198)
      Semin Cancer Biol. 2022 Feb;79:180-196. (PMID: 33249201)
      J Clin Oncol. 2013 Oct 10;31(29):3639-46. (PMID: 24002501)
      Cancer Discov. 2018 Jul;8(7):836-849. (PMID: 29657135)
      N Engl J Med. 2016 Sep 15;375(11):1054-67. (PMID: 27626519)
      Matrix Biol. 2009 Mar;28(2):110-9. (PMID: 19284971)
      Genes (Basel). 2019 Sep 13;10(9):. (PMID: 31540307)
      J Clin Pharmacol. 2015 Sep;55(9):1012-23. (PMID: 25854986)
      Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):349-361. (PMID: 28911730)
      Clin Cardiol. 2020 Feb;43(2):99-107. (PMID: 31825114)
      Anticancer Res. 2011 Jan;31(1):123-7. (PMID: 21273589)
      Recent Pat Anticancer Drug Discov. 2015;10(3):259-69. (PMID: 26152149)
      Future Oncol. 2022 Sep;18(28):3143-3150. (PMID: 35969032)
      J Exp Stroke Transl Med. 2010 Feb 9;3(1):8-18. (PMID: 21423788)
      Oncologist. 2018 Mar;23(3):306-315. (PMID: 29146618)
      Clin Cancer Res. 2021 Oct 15;27(20):5452-5456. (PMID: 34045295)
      Ann Oncol. 2017 Nov 01;28(11):2813-2819. (PMID: 29045520)
      Trends Cancer. 2021 Dec;7(12):1074-1088. (PMID: 34391699)
      Br J Pharmacol. 2018 Sep;175(17):3504-3515. (PMID: 29908090)
      Best Pract Res Clin Endocrinol Metab. 2023 Jan;37(1):101655. (PMID: 35422397)
      Endocr Relat Cancer. 2019 Aug 1;26(9):R499-R518. (PMID: 31252403)
      Ann Oncol. 2021 Mar;32(3):337-350. (PMID: 33455880)
      Pancreas. 2010 Jul;39(5):581-94. (PMID: 20118823)
      Endocr Relat Cancer. 2016 Apr;23(4):R185-205. (PMID: 27207700)
      Hypertension. 2009 Sep;54(3):652-8. (PMID: 19652084)
      Endocr Pract. 2013 Jul-Aug;19(4):703-11. (PMID: 23512389)
      Eur Heart J. 2018 Sep 1;39(33):3021-3104. (PMID: 30165516)
      Endocrine. 2021 Apr;72(1):179-189. (PMID: 32770440)
      Dtsch Arztebl Int. 2018 Aug 20;115(33-34):557-568. (PMID: 30189978)
      ESMO Open. 2021 Jun;6(3):100183. (PMID: 34091261)
      Br J Surg. 2021 Mar 12;108(2):174-181. (PMID: 33704404)
      Thyroid. 2015 Jun;25(6):567-610. (PMID: 25810047)
      Drugs. 2020 Jul;80(11):1119-1124. (PMID: 32557397)
      Nat Rev Cancer. 2013 Dec;13(12):871-82. (PMID: 24263190)
      Circ Res. 2021 Apr 2;128(7):1040-1061. (PMID: 33793337)
      Oncotarget. 2017 May 9;8(41):69477-69492. (PMID: 29050218)
      JAMA Intern Med. 2018 Jan 1;178(1):28-36. (PMID: 29131895)
      Laryngoscope. 2010 Dec;120(12):2446-51. (PMID: 21108428)
      Cancer. 2016 Feb 1;122(3):358-66. (PMID: 26539937)
      N Engl J Med. 2020 Aug 27;383(9):825-835. (PMID: 32846061)
      Curr Hypertens Rev. 2020;16(1):61-72. (PMID: 31622203)
      Int J Mol Sci. 2021 Oct 31;22(21):. (PMID: 34769260)
      Int J Mol Sci. 2018 Oct 20;19(10):. (PMID: 30347815)
      Asian Pac J Cancer Prev. 2019 Jan 25;20(1):277-282. (PMID: 30678450)
    • Contributed Indexing:
      Keywords: adverse effects; cabozantinib; clinical trials; hypertension; medullary thyroid cancer; pralsetinib; selpercatinib; tyrosine kinase inhibitors; vandetanib
    • Accession Number:
      CEGM9YBNGD (selpercatinib)
      0 (pralsetinib)
      1C39JW444G (cabozantinib)
      0 (Protein Kinase Inhibitors)
      0 (Piperidines)
    • Subject Terms:
      Thyroid cancer, medullary
    • Publication Date:
      Date Created: 20230211 Date Completed: 20230214 Latest Revision: 20240912
    • Publication Date:
      20240912
    • Accession Number:
      PMC9917177
    • Accession Number:
      10.3390/ijms24032312
    • Accession Number:
      36768635